Andra AP fonden Acquires 86,900 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Andra AP fonden raised its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 116.8% during the 2nd quarter, Holdings Channel.com reports. The fund owned 161,300 shares of the company’s stock after purchasing an additional 86,900 shares during the quarter. Andra AP fonden’s holdings in Neurocrine Biosciences were worth $22,206,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. International Assets Investment Management LLC boosted its holdings in Neurocrine Biosciences by 7,880.3% in the fourth quarter. International Assets Investment Management LLC now owns 5,666 shares of the company’s stock worth $747,000 after purchasing an additional 5,595 shares during the last quarter. Benjamin F. Edwards & Company Inc. purchased a new stake in Neurocrine Biosciences during the fourth quarter valued at $33,000. National Bank of Canada FI lifted its holdings in Neurocrine Biosciences by 2,192.0% in the fourth quarter. National Bank of Canada FI now owns 22,966 shares of the company’s stock valued at $3,025,000 after acquiring an additional 21,964 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Neurocrine Biosciences by 10.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 686,835 shares of the company’s stock worth $90,497,000 after purchasing an additional 63,568 shares during the last quarter. Finally, Principal Securities Inc. bought a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at about $75,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Insider Activity

In related news, Director William H. Rastetter sold 14,250 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the sale, the director now owns 37,491 shares in the company, valued at approximately $5,499,554.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director William H. Rastetter sold 14,250 shares of the company’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the transaction, the director now directly owns 37,491 shares in the company, valued at approximately $5,499,554.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gary A. Lyons sold 930 shares of the firm’s stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $150.03, for a total transaction of $139,527.90. Following the completion of the sale, the director now directly owns 119,047 shares of the company’s stock, valued at approximately $17,860,621.41. The disclosure for this sale can be found here. Insiders sold 71,798 shares of company stock valued at $10,676,096 in the last ninety days. Insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

NBIX has been the subject of several recent research reports. Jefferies Financial Group boosted their target price on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Cantor Fitzgerald reduced their price objective on Neurocrine Biosciences from $170.00 to $155.00 and set an “overweight” rating for the company in a research note on Thursday, August 29th. Citigroup lifted their target price on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. Royal Bank of Canada cut their price target on Neurocrine Biosciences from $143.00 to $136.00 and set a “sector perform” rating for the company in a report on Thursday, August 29th. Finally, BMO Capital Markets lowered their price objective on Neurocrine Biosciences from $142.00 to $128.00 and set a “market perform” rating on the stock in a research report on Thursday, August 29th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $162.20.

Neurocrine Biosciences Stock Performance

NBIX stock opened at $120.64 on Tuesday. The firm has a fifty day moving average price of $142.33 and a 200 day moving average price of $139.01. Neurocrine Biosciences, Inc. has a fifty-two week low of $103.63 and a fifty-two week high of $157.98. The firm has a market cap of $12.18 billion, a PE ratio of 33.23 and a beta of 0.37.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). The business had revenue of $590.20 million during the quarter, compared to analysts’ expectations of $545.98 million. Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The business’s quarterly revenue was up 30.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.95 earnings per share. On average, equities analysts predict that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.